New York, USA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Global Dyskinesia Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight
Dyskinesia Pipeline constitutes 40+ key companies continuously working towards developing 45+ Dyskinesia treatment therapies, analyzes DelveInsight
DelveInsight’s Dyskinesia Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Dyskinesia pipeline domain.
Some of the essential takeaways from the Dyskinesia Pipeline report:
- DelveInsight’s Dyskinesia Pipeline analysis depicts a robust space with 40+ active players working to develop 45+ Dyskinesia pipeline treatment therapies.
- Some of the key Dyskinesia companies proactively working to develop potential drug candidates to improve the Dyskinesia treatment options include names like Contera Pharma, VistaGen Therapeutics, Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, Teva Pharmaceutical, Luye Pharma Group, IMAC holdings, Neurocrine Biosciences, PolyCore Therapeutics, SOM Biotech, PharmaTher Inc., Appello Pharmaceutical, Sumitomo Pharma, Trevi Therapeutics, Sinopia Bioscience, SAGE Therapeutics, Adhera Therapeutics, and many more.
- Essential Dyskinesia pipeline therapies such as JM-010, CP-011, CPL 500036,NLX-112, Dipraglurant, IRL-790, ML-007, Mesocarb, Ketamine, Deutetrabenazine, LPM-3770164, PCT-3012, AQW051, DSP-9632P, AV-101,T 111, SB-0107, SOM3366, and many others.
- In June 2022, Addex Therapeutics Ltd announced that it had terminated the Phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson’s disease (PD-LID) due to the slow recruitment of patients.
- In March 2022, Neurocrine Biosciences, Inc. announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval for DYSVAL® capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare.
- In November 2021, Neurocrine Biosciences, Inc. announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29–November 1, 2021.
- In April 2022, PolyCore Therapeutics secured seed financing to address motor symptoms and Dyskinesia associated with Parkinson’s Disease.
Request a sample and discover more about the report offerings @ Dyskinesia Emerging Therapies
The Dyskinesia pipeline report lays down detailed profiles of the pipeline assets, a comparative analysis of clinical and non-clinical stage Dyskinesia pipeline products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Dyskinesia pipeline landscape.
Dyskinesia Overview
Dyskinesia’s are involuntary, erratic, writhing movements of the face, arms, legs or trunk. They are often fluid and dance-like, but they may also cause rapid jerking or slow and extended muscle spasms. They are not a symptom of Parkinson's itself. Rather, they are a complication from some Parkinson's medications. They may be caused by systemic, metabolic, endocrinologic, structural, vascular, infectious or inherited degenerative conditions, or be toxin- or drug-induced. Dyskinesia’s usually begin after a few years of treatment with levodopa and can often be alleviated by adjusting dopaminergic medications. Younger people with PD are thought to develop earlier motor fluctuations and dyskinesia’s in response to levodopa.
Find out more about the disease and recent cancer research developments @ Dyskinesia Pipeline Assessment
Dyskinesia Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| JM-010 | Contera Pharma | Phase II | Serotonin 1D receptor agonist | Oral |
| NLX 112 | Neurolixis | Phase II | Serotonin 1A receptor agonists | Oral |
| CPL 500036 | Celon Pharma | Phase II | Phosphodiesterase 10A inhibitor | Oral |
| LPM-3770164 | Luye Pharma Group | Phase I | Vesicular monoamine transporter 2 inhibitor | Oral |
Learn more about the novel and emerging Dyskinesia pipeline therapies @ Dyskinesia Pipeline Analysis
Dyskinesia Pipeline Therapeutics Assessment
The Dyskinesia Pipeline report proffers an integral view of the Dyskinesia emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.
Scope of the Dyskinesia Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Dyskinesia Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Dyskinesia Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
- Therapeutics Assessment By Dyskinesia Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Dyskinesia Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Dyskinesia Mechanism of Action: Serotonin 1A receptor agonist, Serotonin 1B receptor agonist; Serotonin 1D receptor agonist, Phosphodiesterase 10A inhibitor,Vesicular monoamine transporter 2 inhibitor, Opioid kappa receptor agonist, Opioid mu receptor antagonist, Kynurenine modulator, NMDA receptor modulator.
- Key Dyskinesia Companies: Contera Pharma, VistaGen Therapeutics, Neurolixis, Celon Pharma, Addex Therapeutics, IRLAB Therapeutics AB, MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, Teva Pharmaceutical, Luye Pharma Group, IMAC holdings, Neurocrine Biosciences, PolyCore Therapeutics, SOM Biotech, PharmaTher Inc., Novartis Pharmaceuticals, Sumitomo Pharma, Trevi Therapeutics, Sinopia Bioscience, Adhera Therapeutics, SAGE Therapeutics, and many more.
- Key Dyskinesia Pipeline Therapies: JM-010, CP-011, CPL 500036,NLX-112, Dipraglurant, IRL-790, ML-007, Mesocarb, Ketamine, Deutetrabenazine, LPM-3770164, PCT-3012, AQW051, DSP-9632P, AV-101,T 111, SB-0107, SOM3366, and many others.
Dive deep into rich insights for emerging therapies and assessment, visit @ Dyskinesia Pipeline and Emerging Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Dyskinesia: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Late Stage Products (Phase III) |
| 6 | Mid Stage Products (Phase II) |
| 6.1 | JM-010: Contera Pharma |
| 7 | Early Stage Products (Phase I) |
| 7.1 | LPM-3770164: Luye Pharma Group |
| 8 | Preclinical and Discovery Stage Products |
| 9 | Inactive Products |
| 10 | Collaborations Assessment- Licensing / Partnering / Funding |
| 11 | Dyskinesia - Unmet Needs |
| 12 | Dyskinesia - Market Drivers and Barriers |
| 13 | Appendix |
| 14 | About DelveInsight |
For further information on the current Dyskinesia pipeline therapeutics, reach out @ Dyskinesia Ongoing Clinical Trials
Related Reports
Dyskinesia Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Dyskinesia companies, including MAPLIGHT THERAPEUTICS, Melior Pharmaceuticals, Molomics, Teva Pharmaceutical, Luye Pharma Group, among others.
Dyskinesia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Dyskinesia epidemiology in the 7MM.
Primary Ciliary Dyskinesia Pipeline
Primary Ciliary Dyskinesia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Primary Ciliary Dyskinesia companies, including Parion Sciences, Translate Bio, ReCode Therapeutics, among others.
Primary Ciliary Dyskinesia Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key Primary Ciliary Dyskinesia companies, including Parion Sciences, Translate Bio, ReCode Therapeutics, among others.
Tardive Dyskinesia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Tardive Dyskinesia companies, including SOM Biotech, Teva Pharmaceutical, Contera Pharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
